plenty of doubting Thomases out there mate, they won’t believe till they can see it, and even after seeing, they’ll need to touch it
The violent wake up point will be when Mr Market realizes the distinction between general medicine vs precision medicine. It’ll start scrambling for the correct probability parameters to assign to PYC’s pipeline of pre-clinical leads, and might then start digging deeper to our patent pipeline.
This is where us on this thread differ from the general population in that we’re roughly a year ahead of the story arc; I love the IMU story, but PYC playing in the RNA precision medicine space provides a totally different upshot potential
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)